Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Azoth Analytics | PRODUCT CODE: 1718919

Cover Image

PUBLISHER: Azoth Analytics | PRODUCT CODE: 1718919

Global Cancer Vaccine Market (2025 Edition): Analysis By Type (Preventative, Therapeutic), By Technology Type, By Region, By Country: Market Insights and Forecast (2021-2031)

PUBLISHED:
PAGES: 203 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2450
PDF (Enterprise License)
USD 2950

Add to Cart

Executive Summary

Azoth Analytics has released a research report titled "Global Cancer Vaccine Market (2025 Edition)" which provides a complete analysis of the Global Cancer Vaccine industry in terms of market segmentation By Type (Preventative, Therapeutic), By Technology Type (Recombinant Vaccine, Whole cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies) for the historical period of 2021-2024, the estimates of 2025 and the forecast period of 2026-2031.

The report analyses the Cancer Vaccine Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Cancer Vaccine market showcased growth at a CAGR of 6.68% during 2021-2024. The market was valued at USD 12165.62 Million in 2024 which is expected to reach USD 20883.55 Million in 2031.

The Cancer Vaccine Market is driven by innovations in immuno-oncology, increased prevalence of cancer, and growing investment in personalized medicine and biologics.

Preventative vaccines continue to dominate market share, particularly due to the success of HPV vaccination campaigns and government-supported immunization initiatives. Therapeutic vaccines are also witnessing increased adoption owing to advances in precision immunotherapy and their potential to treat a broad range of cancers by stimulating the patient's immune response.

From a technology perspective, Recombinant Vaccines hold a major share in the market, fueled by their high efficacy, safety profile, and increasing R&D activities. Other emerging platforms such as viral vector-based and DNA-based vaccines are gaining traction, especially in clinical development pipelines.

Regionally, Americas leads the market, attributed to the presence of advanced healthcare infrastructure, high awareness, and strong regulatory support for vaccine development. However, Asia Pacific is expected to experience the fastest growth rate during the forecast period, driven by rising cancer incidence, increasing healthcare expenditure, and expanding biotechnology capabilities in countries such as China and India.

Scope of the Report:

  • The report analyses the Cancer Vaccine Market by Value (USD Million).
  • The report presents the analysis of Cancer Vaccine Market for the historical period of 2021-2024, the estimated year 2025 and the forecast period of 2026-2031.
  • The report analyses the Cancer Vaccine Market By Type (Preventative, Therapeutic)
  • The report analyses the Cancer Vaccine Market By Technology Type (Recombinant Vaccine, Whole cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, and By Technology Type.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Merck & Co., Inc., Amgen Inc., Bristol Myers Squibb, GSK plc, Moderna, Inc., BioNTech SE, Dendreon Pharmaceuticals LLC, Gritstone bio, Inc., Nouscom S.r.l., and Immunomic Therapeutics, Inc.

Table of Content

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Analyst Recommendations

  • 2.1 Leveraging AI and Bioinformatics for Precision Cancer Vaccine Development
  • 2.2 Pursue Fast-Track and Orphan Drug Designations

3. Global Cancer Vaccine Market: Historic and Forecast

  • 3.1 Impact Analysis of Macro Economic Factors on Cancer Vaccine Market
  • 3.2 Prevalence and Incidence of Total cancers, Worldwide
  • 3.3 Global Cancer Vaccination Coverage
  • 3.4 Global Cancer Vaccine Market: Dashboard
  • 3.5 Global Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
  • 3.6 Global Cancer Vaccine Market: Market Value Assessment
  • 3.7 Global Cancer Vaccine Market Segmentation: By Type
    • 3.7.1 Global Cancer Vaccine Market, By Type Overview
    • 3.7.2 Global Cancer Vaccine Market Attractiveness Index, By Type
    • 3.7.3 Global Cancer Vaccine Market Size, By Preventative, By Value, 2021H-2031F (USD Million & CAGR)
    • 3.7.4 Global Cancer Vaccine Market Size, By Therapeutic, By Value, 2021H-2031F (USD Million & CAGR)
  • 3.8 Global Cancer Vaccine Market Segmentation: By Technology Type
    • 3.8.1 Global Cancer Vaccine Market, By Technology Type Overview
    • 3.8.2 GlobalCancer Vaccine Market Attractiveness Index, By Technology Type
    • 3.8.3 Global Cancer Vaccine Market Size, By Recombinant Vaccine, By Value, 2021H-2031F (USD Million & CAGR)
    • 3.8.4 Global Cancer Vaccine Market Size, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 3.8.5 Global Cancer Vaccine Market Size, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 3.8.6 Global Cancer Vaccine Market Size, By Other Technologies, By Value, 2021H-2031F (USD Million & CAGR)

4. Cancer Vaccine Market, Region Analysis

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Cancer Vaccine Market: Historic and Forecast

  • 5.1 Americas Cancer Vaccine Market: Snapshot
  • 5.2 Americas Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
  • 5.3 Americas Cancer Vaccine Market: Key Factors
  • 5.4 Americas Cancer Vaccine Market: Segment Analysis
  • 5.5 Americas Cancer Vaccine Market Segmentation: By Type
    • 5.5.1 Americas Cancer Vaccine Market, By Type Overview
    • 5.5.2 Americas Cancer Vaccine Market Size, By Preventative, By Value, 2021H-2031F (USD Million & CAGR)
    • 5.5.3 Americas Cancer Vaccine Market Size, By Therapeutic, By Value, 2021H-2031F (USD Million & CAGR)
  • 5.6 Americas Cancer Vaccine Market Segmentation: By Technology Type
    • 5.6.1 Americas Cancer Vaccine Market, By Technology Type Overview
    • 5.6.2 Americas Cancer Vaccine Market Size, By Recombinant Vaccine, By Value, 2021H-2031F (USD Million & CAGR)
    • 5.6.3 Americas Cancer Vaccine Market Size, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 5.6.4 Americas Cancer Vaccine Market Size, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 5.6.5 Americas Cancer Vaccine Market Size, By Other Technologies, By Value, 2021H-2031F (USD Million & CAGR)
  • 5.7 Americas Cancer Vaccine Market Segmentation: By Country
    • 5.7.1 Americas Cancer Vaccine Market, by Country Overview
    • 5.7.2 United States Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 5.7.2.1 United States Cancer Vaccine Market, By Type
      • 5.7.2.2 United States Cancer Vaccine Market, By Technology Type
    • 5.7.3 Canada Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 5.7.3.1 Canada Cancer Vaccine Market, By Type
      • 5.7.3.2 Canada Cancer Vaccine Market, By Technology Type
    • 5.7.4 Rest of Americas Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 5.7.4.1 Rest of Americas Cancer Vaccine Market, By Type
      • 5.7.4.2 Rest of Americas Cancer Vaccine Market, By Technology Type

6. Europe Cancer Vaccine Market: Historic and Forecast

  • 6.1 Europe Cancer Vaccine Market: Snapshot
  • 6.2 Europe Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
  • 6.3 Europe Cancer Vaccine Market: Key Factors
  • 6.4 Europe Cancer Vaccine Market: Segment Analysis
  • 6.5 Europe Cancer Vaccine Market Segmentation: By Type
    • 6.5.1 Europe Cancer Vaccine Market, By Type Overview
    • 6.5.2 Europe Cancer Vaccine Market Size, By Preventative, By Value, 2021H-2031F (USD Million & CAGR)
    • 6.5.3 Europe Cancer Vaccine Market Size, By Therapeutic, By Value, 2021H-2031F (USD Million & CAGR)
  • 6.6 Europe Cancer Vaccine Market Segmentation: By Technology Type
    • 6.6.1 Europe Cancer Vaccine Market, By Technology Type Overview
    • 6.6.2 Europe Cancer Vaccine Market Size, By Recombinant Vaccine, By Value, 2021H-2031F (USD Million & CAGR)
    • 6.6.3 Europe Cancer Vaccine Market Size, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 6.6.4 Europe Cancer Vaccine Market Size, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 6.6.5 Europe Cancer Vaccine Market Size, By Other Technologies, By Value, 2021H-2031F (USD Million & CAGR)
  • 6.7 Europe Cancer Vaccine Market Segmentation: By Country
    • 6.7.1 Europe Cancer Vaccine Market, by Country Overview
    • 6.7.2 Germany Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 6.7.2.1 Germany Cancer Vaccine Market, By Type
      • 6.7.2.2 Germany Cancer Vaccine Market, By Technology Type
    • 6.7.3 United Kingdom Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 6.7.3.1 United Kingdom Cancer Vaccine Market, By Type
      • 6.7.3.2 United Kingdom Cancer Vaccine Market, By Technology Type
    • 6.7.4 France Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 6.7.4.1 France Cancer Vaccine Market, By Type
      • 6.7.4.2 France Cancer Vaccine Market, By Technology Type
    • 6.7.5 Italy Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 6.7.5.1 Italy Cancer Vaccine Market, By Type
      • 6.7.5.2 Italy Cancer Vaccine Market, By Technology Type
    • 6.7.6 Spain Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 6.7.6.1 Spain Cancer Vaccine Market, By Type
      • 6.7.6.2 Spain Cancer Vaccine Market, By Technology Type
    • 6.7.7 Rest of Europe Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 6.7.7.1 Rest of Europe Cancer Vaccine Market, By Type
      • 6.7.7.2 Rest of Europe Cancer Vaccine Market, By Technology Type

7. Asia Pacific Cancer Vaccine Market: Historic and Forecast

  • 7.1 Asia Pacific Cancer Vaccine Market: Snapshot
  • 7.2 Asia Pacific Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
  • 7.3 Asia Pacific Cancer Vaccine Market: Key Factors
  • 7.4 Asia Pacific Cancer Vaccine Market: Segment Analysis
  • 7.5 Asia Pacific Cancer Vaccine Market Segmentation: By Type
    • 7.5.1 Asia Pacific Cancer Vaccine Market, By Type Overview
    • 7.5.2 Asia Pacific Cancer Vaccine Market Size, By Preventative, By Value, 2021H-2031F (USD Million & CAGR)
    • 7.5.3 Asia Pacific Cancer Vaccine Market Size, By Therapeutic, By Value, 2021H-2031F (USD Million & CAGR)
  • 7.6 Asia Pacific Cancer Vaccine Market Segmentation: By Technology Type
    • 7.6.1 Asia Pacific Cancer Vaccine Market, By Technology Type Overview
    • 7.6.2 Asia Pacific Cancer Vaccine Market Size, By Recombinant Vaccine, By Value, 2021H-2031F (USD Million & CAGR)
    • 7.6.3 Asia Pacific Cancer Vaccine Market Size, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 7.6.4 Asia Pacific Cancer Vaccine Market Size, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 7.6.5 Asia Pacific Cancer Vaccine Market Size, By Other Technologies, By Value, 2021H-2031F (USD Million & CAGR)
  • 7.7 Asia Pacific Cancer Vaccine Market Segmentation: By Country
    • 7.7.1 Asia Pacific Cancer Vaccine Market, by Country Overview
    • 7.7.2 China Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 7.7.2.1 China Cancer Vaccine Market, By Type
      • 7.7.2.2 China Cancer Vaccine Market, By Technology Type
    • 7.7.3 Japan Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 7.7.3.1 Japan Cancer Vaccine Market, By Type
      • 7.7.3.2 Japan Cancer Vaccine Market, By Technology Type
    • 7.7.4 India Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 7.7.4.1 India Cancer Vaccine Market, By Type
      • 7.7.4.2 India Cancer Vaccine Market, By Technology Type
    • 7.7.5 Rest of Asia Pacific Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
      • 7.7.5.1 Rest of Asia Pacific Cancer Vaccine Market, By Type
      • 7.7.5.2 Rest of Asia Pacific Cancer Vaccine Market, By Technology Type

8. Middle East and Africa Cancer Vaccine Market: Historic and Forecast

  • 8.1 Middle East and Africa Cancer Vaccine Market: Snapshot
  • 8.2 Middle East and Africa Cancer Vaccine Market: Market Size and CAGR, 2021-2031 (USD Million & CAGR)
  • 8.3 Middle East and Africa Cancer Vaccine Market: Key Factors
  • 8.4 Middle East and Africa Cancer Vaccine Market: Segment Analysis
  • 8.5 Middle East and Africa Cancer Vaccine Market Segmentation: By Type
    • 8.5.1 Middle East and Africa Cancer Vaccine Market, By Type Overview
    • 8.5.2 Middle East and Africa Cancer Vaccine Market Size, By Preventative, By Value, 2021H-2031F (USD Million & CAGR)
    • 8.5.3 Middle East and Africa Cancer Vaccine Market Size, By Therapeutic, By Value, 2021H-2031F (USD Million & CAGR)
  • 8.6 Middle East and Africa Cancer Vaccine Market Segmentation: By Technology Type
    • 8.6.1 Middle East and Africa Cancer Vaccine Market, By Technology Type Overview
    • 8.6.2 Middle East and Africa Cancer Vaccine Market Size, By Recombinant Vaccine, By Value, 2021H-2031F (USD Million & CAGR)
    • 8.6.3 Middle East and Africa Cancer Vaccine Market Size, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 8.6.4 Middle East and Africa Cancer Vaccine Market Size, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Million & CAGR)
    • 8.6.5 Middle East and Africa Cancer Vaccine Market Size, By Other Technologies, By Value, 2021H-2031F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact assessment of Market Dynamics on Cancer Vaccine Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10 Industry Ecosystem Analysis

  • 10.1 Porter Analysis

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Position Matrix
  • 11.3 Market Share Analysis of Cancer Vaccine Market
  • 11.4 Company Profiles
    • 11.4.1 Merck & Co., Inc.
    • 11.4.2 Amgen Inc.
    • 11.4.3 Bristol Myers Squibb
    • 11.4.4 GSK plc
    • 11.4.5 Moderna, Inc.
    • 11.4.6 BioNTech SE
    • 11.4.7 Dendreon Pharmaceuticals LLC
    • 11.4.8 Gritstone bio, Inc.
    • 11.4.9 Nouscom S.r.l.
    • 11.4.10 Immunomic Therapeutics, Inc.

12. About Us & Disclaimer

List of Figures

  • Figure 1: Prevalence and Incidence of Total cancers, Worldwide
  • Figure 2: Global Cancer Vaccine Market Size, By Value, 2021-2024 (USD Million)
  • Figure 3: Global Cancer Vaccine Market Size, By Value, 2025-2031 (USD Million)
  • Figure 4: Global Cancer Vaccine Market Share, By Type, 2024 (%)
  • Figure 5: Market Attractiveness Analysis of Cancer Vaccine Market, By Type (2026-2031)
  • Figure 6: Global Cancer Vaccine Market Size, By Preventative, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 7: Global Cancer Vaccine Market Absolute Opportunity, By Preventative, 2021-2031 (USD Million)
  • Figure 8: Global Cancer Vaccine Market Size, By Therapeutic, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 9: Global Cancer Vaccine Market Absolute Opportunity, By Therapeutic, 2021-2031 (USD Million)
  • Figure 10: Market Attractiveness Analysis of Cancer Vaccine Market, By Technology Type (2026-2031)
  • Figure 11: Global Cancer Vaccine Market Size, By Recombinant Vaccine, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 12: Global Cancer Vaccine Market Absolute Opportunity, By Recombinant Vaccine, 2021-2031 (USD Million)
  • Figure 13: Global Cancer Vaccine Market Size, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 14: Global Cancer Vaccine Market Absolute Opportunity, By Whole Cell Cancer Vaccines, 2021-2031 (USD Million)
  • Figure 15: Global Cancer Vaccine Market Size, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 16: Global Cancer Vaccine Market Absolute Opportunity, By Viral Vector and DNA Cancer Vaccines, 2021-2031 (USD Million)
  • Figure 17: Global Cancer Vaccine Market Size, By Other Technologies, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 18: Global Cancer Vaccine Market Absolute Opportunity, By Other Technologies, 2021-2031 (USD Million)
  • Figure 19: Americas Cancer Vaccine Market Size, By Value, 2021H-2031F (USD Million)
  • Figure 20: Americas Cancer Vaccine Market Share, By Type, 2024 (%)
  • Figure 21: Americas Cancer Vaccine Market, By Preventative, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 22: Americas Cancer Vaccine Market, By Therapeutic, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 23: Americas Cancer Vaccine Market, By Recombinant Vaccine, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 24: Americas Cancer Vaccine Market, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 25: Americas Cancer Vaccine Market, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 26: Americas Cancer Vaccine Market, By Other Technologies, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 27: United States Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 28: United States Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 29: United States Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 30: United States Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 31: Canada Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 32: Canada Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 33: Canada Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 34: Canada Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 35: Rest of Americas Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 36: Rest of Americas Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 37: Rest of Americas Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 38: Rest of Americas Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 39: Europe Cancer Vaccine Market Size, By Value, 2021H-2031F (USD Million)
  • Figure 40: Europe Cancer Vaccine Market Share, By Type, 2024 (%)
  • Figure 41: Europe Cancer Vaccine Market, By Preventative, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 42: Europe Cancer Vaccine Market, By Therapeutic, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 43: Europe Cancer Vaccine Market, By Recombinant Vaccine, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 44: Europe Cancer Vaccine Market, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 45: Europe Cancer Vaccine Market, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 46: Europe Cancer Vaccine Market, By Other Technologies, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 47: Germany Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 48: Germany Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 49: Germany Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 50: Germany Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 51: United Kingdom Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 52: United Kingdom Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 53: United Kingdom Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 54: United Kingdom Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 55: France Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 56: France Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 57: France Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 58: France Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 59: Italy Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 60: Italy Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 61: Italy Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 62: Italy Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 63: Spain Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 64: Spain Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 65: Spain Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 66: Spain Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 67: Rest of Europe Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 68: Rest of Europe Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 69: Rest of Europe Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 70: Rest of Europe Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 71: Asia Pacific Cancer Vaccine Market Size, By Value, 2021H-2031F (USD Million)
  • Figure 72: Asia Pacific Cancer Vaccine Market Share, By Type, 2024 (%)
  • Figure 73: Asia Pacific Cancer Vaccine Market, By Preventative, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 74: Asia Pacific Cancer Vaccine Market, By Therapeutic, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 75: Asia Pacific Cancer Vaccine Market, By Recombinant Vaccine, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 76: Asia Pacific Cancer Vaccine Market, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 77: Asia Pacific Cancer Vaccine Market, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 78: Asia Pacific Cancer Vaccine Market, By Other Technologies, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 79: China Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 80: China Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 81: China Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 82: China Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 83: Japan Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 84: Japan Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 85: Japan Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 86: Japan Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 87: India Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 88: India Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 89: India Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 90: India Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 91: Rest of Asia Pacific Cancer Vaccine Market, By Value, 2021-2031 (USD Millions & CAGR)
  • Figure 92: Rest of Asia Pacific Cancer Vaccine Market Value, By Type, 2024 (USD Million)
  • Figure 93: Rest of Asia Pacific Cancer Vaccine Market Share, By Type, By Value, 2024 (%)
  • Figure 94: Rest of Asia Pacific Cancer Vaccine Market Share, By Technology Type, By Value, 2024 (%)
  • Figure 95: Middle East and Africa Cancer Vaccine Market Size, By Value, 2021H-2031F (USD Million)
  • Figure 96: Middle East and Africa Cancer Vaccine Market Share, By Type, 2024 (%)
  • Figure 97: Middle East and Africa Cancer Vaccine Market, By Preventative, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 98: Middle East and Africa Cancer Vaccine Market, By Therapeutic, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 99: Middle East and Africa Cancer Vaccine Market, By Recombinant Vaccine, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 100: Middle East and Africa Cancer Vaccine Market, By Whole Cell Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 101: Middle East and Africa Cancer Vaccine Market, By Viral Vector and DNA Cancer Vaccines, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 102: Middle East and Africa Cancer Vaccine Market, By Other Technologies, By Value, 2021H-2031F (USD Millions & CAGR)
  • Figure 103: Market Share of Prominent Companies of Cancer Vaccine Market, 2024 (%)
  • Figure 104: Merck & Co., Inc. Revenues, 2022-2024 (USD Million)
  • Figure 105: Merck & Co., Inc. Revenues, By Geographic Segments, 2024 (%)
  • Figure 106: Merck & Co., Inc. Revenue , By Business Segments, 2024 (%)
  • Figure 107: Amgen Revenues, 2022-2024 (USD Million)
  • Figure 108: Amgen Revenues, By Geographic Segments, 2024 (%)
  • Figure 109: Amgen Revenue , By Business Segments, 2024 (%)
  • Figure 110: Bristol Myers Squibb Revenues, 2022-2024 (USD Million)
  • Figure 111: Bristol Myers Squibb Revenues, By Geographic Segments, 2024 (%)
  • Figure 112: Bristol Myers Squibb Revenue , By Products, 2024 (%)
  • Figure 113: GSK plc Revenues, 2022-2024 (USD Million)
  • Figure 114: GSK plc Revenues, By Geographic Segments, 2024 (%)
  • Figure 115: GSK plc Revenue , By Products, 2024 (%)
  • Figure 116: Moderna, Inc Revenues, 2022-2024 (USD Million)
  • Figure 117: Moderna, Inc Revenues, By Geographic Segments, 2024 (%)
  • Figure 118: BioNTech SE Revenues, 2022-2024 (USD Million)

List of Tables

  • Table A1: Global Impact of Macro Economic Factors, By Region
  • Table A2: Global Cancer Vaccination Coverage
  • Table A3: United States Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A4: United States Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A5: United States Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A6: United States Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A7: Canada Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A8: Canada Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A9: Canada Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A10: Canada Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A11: Rest of Americas Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A12: Rest of Americas Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A13: Rest of Americas Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A14: Rest of Americas Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A15: Germany Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A16: Germany Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A17: Germany Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A18: Germany Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A19: United Kingdom Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A20: United Kingdom Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A21: United Kingdom Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A22: United Kingdom Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A23: France Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A24: France Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A25: France Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A26: France Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A27: Italy Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A28: Italy Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A29: Italy Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A30: Italy Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A31: Spain Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A32: Spain Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A33: Spain Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A34: Spain Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A35: Rest of Europe Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A36: Rest of Europe Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A37: Rest of Europe Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A38: Rest of Europe Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A39: China Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A40: China Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A41: China Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A42: China Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A43: Japan Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A44: Japan Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A45: Japan Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A46: Japan Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A47: India Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A48: India Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A49: India Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A50: India Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A51: Rest of Asia Pacific Cancer Vaccine Market, By Type, By Value, 2021-2024 (USD Million)
  • Table A52: Rest of Asia Pacific Cancer Vaccine Market, By Type, By Value, 2025-2031 (USD Million)
  • Table A53: Rest of Asia Pacific Cancer Vaccine Market, By Technology Type, By Value, 2021-2024 (USD Million)
  • Table A54: Rest of Asia Pacific Cancer Vaccine Market, By Technology Type, By Value, 2025-2031 (USD Million)
  • Table A55: Merck & Co., Inc. Key Financials, 2022-2024
  • Table A56: Amgen Key Financials, 2022-2024
  • Table A57: Bristol Myers Squibb Key Financials, 2022-2024
  • Table A58: GSK plc Key Financials, 2022-2024
  • Table A59: Moderna, Inc Key Financials, 2022-2024
  • Table A60: BioNTech SE Key Financials, 2022-2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!